|Clinical trial shows efficacy for atezolizumab combined with carboplatin
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.
Friday, December 15th, 2023
|New members of Academy for Excellence in Clinical Medicine selected
Vanderbilt University School of Medicine Academy for Excellence in Clinical Medicine (AECM) has selected 25 new members.
Friday, December 15th, 2023
|International workgroup of geneticists issues CHEK2 guidelines
International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.
Wednesday, July 26th, 2023
|Pal named to cancer research national leadership posts
Tuya Pal, MD, Ingram Professor of Cancer Research and associate director for Cancer Health Disparities at Vanderbilt-Ingram Cancer Center, has been named to two cancer research leadership posts.
Monday, December 28th, 2020
|New therapeutic target for lung cancer
Continuous activation of cell surface receptors increases signaling that can promote oncogenic transformation. One receptor, EphA2, has been identified as a driver of lung cancer, but its interacting partners are not well characterized.
Thursday, November 12th, 2020
|Park named director of Hematology and Oncology at VICC
After serving as interim director since Jan. 1, Ben Ho Park, MD, PhD, Donna S. Hall Professor of Breast Cancer Research at Vanderbilt University Medical Center, has been named director of the Division of Hematology and Oncology.
Wednesday, October 21st, 2020
|Balko lands Mary Kay Foundation grant for breast cancer research
Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.
Friday, December 6th, 2019
|Pietenpol, Wilson land Komen cancer research support
Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.
Thursday, October 24th, 2019
|Study backs genetic testing for all metastatic breast cancer patients
Testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies.
Friday, September 6th, 2019
|Grant strengthens breast cancer research efforts
Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.
Saturday, August 31st, 2019
|Encephalitis identified as rare toxicity of immunotherapy treatment
Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Monday, July 22nd, 2019
|A critical factor for wound healing
Vanderbilt-Ingram Cancer Center scientists have discovered a role for a tumor suppressor protein in skin wound healing.
Friday, July 19th, 2019
|Breast cancer-killing RIG
A recent study in the journal Cancer Research demonstrates that a RIG-I agonist has potent immunogenic and therapeutic effects in breast cancer.
Friday, December 14th, 2018
|VICC breast cancer leaders named Komen Scholars
Ingrid Mayer, MD, MSCI, Ingram Professor of Cancer Research and leader of the Breast Cancer Research Program, has been named a Komen Scholar for her leadership in breast cancer research. She is joined by Wayne Dornan, PhD, a patient research advocate at VICC, who will serve on the Advocates in Science Steering Committee for Susan G. Komen.
Friday, April 13th, 2018
|Study seeks to boost breast tumor immune response
Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.
Thursday, February 8th, 2018
|Study to test combination therapy for breast cancer
Vanderbilt-Ingram Cancer Center has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.
Friday, October 27th, 2017
|Investigators match novel cancer mutations with potential therapies
Research led by Vanderbilt-Ingram Cancer Center (VICC) investigators may have solved a mystery about why a targeted therapy stops working in a small group of breast cancer patients. They identified a novel gene mutation that develops in the tumors, and then found a different cancer drug that appears to treat the newly identified mutation. The […]
Monday, August 7th, 2017
|Drivers of breast cancer metastasis
Overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 25 percent of breast cancers and is associated with poor outcomes. HER2-amplified breast cancers use signaling through a complex of proteins called mTORC2 to drive tumor formation, tumor cell survival and resistance to HER2-targeted therapies. Rebecca Cook, Ph.
Thursday, July 27th, 2017
|Breast cancer program lands new research grants
Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients. The grants totaling more than $3 million will fund mechanistic science and clinical trials designed to test novel therapy combinations and determine why some forms of breast cancer become resistant […]
Friday, March 24th, 2017
|Study details rare heart risk of certain cancer therapies
Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side effects linked to an unexpected immune response. In a study led by Vanderbilt University Medical Center (VUMC) investigators and published in the Nov. 3 issue of the New England Journal of Medicine, researchers describe two cases of […]
Monday, November 7th, 2016
|VICC investigators in spotlight at AACR conference
A top Vanderbilt-Ingram Cancer Center (VICC) investigator recently met with Vice President Joe Biden regarding the National Cancer Moonshot Initiative, a major national program to identify, fund and accelerate the most promising research leading to cancer cures. Carlos L. Arteaga, M.
Thursday, May 19th, 2016
|Study explores how some breast cancers resist treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies. The new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators has identified gene alterations […]
Thursday, April 21st, 2016